Major depressive disorder (MDD) affects more than 350 million people world-wide. Large heterogeneities in patient symptoms has led to several different treatment courses. Although treatments, such as SSRIs, are generally effective, a large portion of patients (~30%) do not achieve remission. The ability to predict which treatment option will yield the best outcome would be of great use to clinicians and patients. The GABAergic system is implicated in MDD and affected by SSRIs. In this study GABA concentrations were measured with MEGA-PRESS MRS in MDD patients before and after treatment with a SSRI to determine predictive ability and treatment changes.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords